Biomea Fusion

Biomea Fusion

  • Founded: 2017
  • Location: Redwood City, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Diabetes (2)
  • Drug types: ONC, END
  • Lead product: BMF-219
  • Product link:
  • Funding: $172.5M stock Mar 2023; $153M IPO Apr 2021; $56M A Jan 2021

job board

Short description:

Small Molecules Targeting Cancer

Drug notes:

Also 7 trials Clin1 multiple cancers; BMF-500 Clin0 AML, CLL; undisclosed RD oncology

Long description:

Biomea Fusion is developing novel small molecules to treat genetically defined diseases with high unmet need. Genetically defined diseases have biomarker-identifiable patient populations that Biomea can target with in silico designed small molecules with new mechanisms of action. This approach employs Biomea’s FUSIONTM System discovery platform that uses novel chemical scaffolds and a computational platform to produce optimized product profiles with high potency and safety. Biomea’s research and development has so far produced three novel, covalent inhibitor programs. Biomea recently received FDA clearance for IND application for their oral menin inhibitor, BMF-219, in type 2 diabetes. BMF-219 is also being developed as a cancer therapy.


Biomea Fusion
Research Associate Contractor
San Carlos, California|9 days ago
Biomea Fusion
Clinical Scientist - Sr. Clinical Scientist - Type...
Redwood City, California|39 days ago
Biomea Fusion
Medical Director - Diabetes
Redwood City, California|55 days ago
Biomea Fusion
Director, Chemical Development & Drug Substance Ma...
Redwood City, California|66 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy